drug_type
RELEVANT_DRUG
intervention_type
Antibody–Drug Conjugate
drug_description
A TROP-2–targeting humanized monoclonal antibody linked via a hydrolyzable linker to SN-38, a topoisomerase I inhibitor; binds TROP-2, internalizes, and can release SN-38 extracellularly to induce DNA damage with a bystander effect in TROP-2–positive tumors.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Sacituzumab govitecan
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized monoclonal antibody targeting TROP-2 linked via a hydrolyzable linker to SN-38 (topoisomerase I inhibitor). Upon binding TROP-2 on tumor cells, the ADC is internalized and/or releases SN-38 extracellularly, causing DNA damage and cell death with a bystander effect in TROP-2–positive tumors.
drug_name
Sacituzumab govitecan (SG)
nct_id_drug_ref
NCT06504719